PICOSSIBLE (04-03)
Approved for use through 07/10/2008 (04/03)
Approved for use through 07/10/2008 (04/03) (04/03)
U.S. Peletra att (14/04/mail 07/04/2008)
U.S. Peletra att (14/04/mail 07/04/2008)
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of inflammation unless of contains a value of the contains and unless of contains a value.

	Filing Date		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	JANS	EN
(Not for submission under 37 CFR 1.99)	Art Unit		
(Not for Submission and or or it is a	Examiner Name		

Application Number		
Filing Date		
First Named Inventor JANS		SEN
Art Unit		
Examiner Name		
Attorney Docket Number		DVME-1031US

U.S.PATENTS								Remove			
Examiner Initial*	Cite No	Patent Number Nind Issue Date Name of Patentee of Applicant			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear						
	1	6473842		2002-1	0-29	TSUTSUMI					
	2	6038571		2000-0	3-14	NUMAJIRI					
3 5423017 1985-06-06 PARIKH											
If you wish to add additional U.S. Patent citation information please click the Add button.											
U.S.PATENT APPLICATION PUBLICATIONS Remove											
Examiner Initial*	xaminer Cite No Publication Number Kind Code1 Date Name of Patentee or Applicant of cited Document				Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear						
	1										
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d button	Add		
FOREIGN PATENT DOCUMENTS Remove											
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²			Publication Date	Name of Patente Applicant of cited Document	e or	where Rele	or Relevant	Ts
	1										

	Application Number		
NEODMATION DIOCE COURT	Filing Date		
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	JANS	EN
Not for submission under 37 CFR 1.99)	Art Unit		
,	Examiner Name		
	Attorney Docket Numb	or	DVME-1031US

If you wish	h to a	dd add	itional Foreign Patent Document citation information please	e click the Add butto	n Add			
NON-PATENT LITERATURE DOCUMENTS Remove								
Examiner Cite Initials* Cite No No Cite No Cit					Тs			
	A. S. TANENBAUM. XP-002297574, Modern Operating Systems (Second Edition), 2001, pgs. 132-153 and 202-237 ISBN: 0-13-031338-0.							
If you wish to add additional non-patent literature document citation information please click the Add button Add								
			EXAMINER SIGNATURE					
Examiner Signature Date Considered								

16e Knr. Oxee of USPTO Patent Documents at were USPTO_GOV or MPEP 901.64. I Enter office that issued the document, by the Involetor code (WIPO Standard ST.3). "For Implantee patent for Comment, he crickless on the year of the Implant or precede the sent and replant document." I Knr. of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. "Applicant is to place a check mark here if English languages the resistation is attached."

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Application Number Filing Date Filing Date Filing Date First Number Investment JANSEN Art Unit Examiner Name Attorney Docket Number | DWMS-1031US

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and	1.98 to make the appropriate selection(s):	
----------------------------	--	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 1.97(eVI.)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 15(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) for the control of the control o

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/KEVIN J. DUNLEAVY/	Date (YYYY-MM-DD)	2006-05-31
Name/Print	KEVIN J. DUNLEAVY	Registration Number	32024

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.